Interference of angiotensin II and enalapril with hepatic blood flow regulation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 6, 2014, Pages G655-G663

  Pereira, Adriano J ^a   Jeger, Victor ^a,c   Fahrner, René ^b   Djafarzadeh, Siamak ^a   Lensch, Michael ^a   Takala, Jukka ^a   Jakob, Stephan M ^a  

^a Departments of Intensive Care Medicine   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibitor; Enalapril; Hepatic artery buffer response

Indexed keywords

ANGIOTENSIN II; ENALAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ARTERY PERFUSION; ARTICLE; BRAIN BLOOD FLOW; CAROTID ARTERY FLOW; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; EXPERIMENTAL PIG; EXPERIMENTAL STUDY; FEMORAL ARTERY FLOW; HEART OUTPUT; HEPATIC ARTERIAL BUFFER RESPONSE; HEPATIC ARTERIAL PERFUSION; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERIPHERAL CIRCULATION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; REGIONAL PERFUSION; ANGIOTENSIN-CONVERTING ENZYME INHIBITOR; ANIMAL; ARTERIAL PRESSURE; BRAIN CIRCULATION; CAROTID ARTERY; DOSE RESPONSE; DRUG EFFECT; HEMODYNAMICS; HEPATIC ARTERY; HEPATIC ARTERY BUFFER RESPONSE; KIDNEY CIRCULATION; LIVER CIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL VEIN; RENAL ARTERY; SWINE; TIME;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITOR; ENALAPRIL; HEPATIC ARTERY BUFFER RESPONSE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIAL PRESSURE; CARDIAC OUTPUT; CAROTID ARTERIES; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HEMODYNAMICS; HEPATIC ARTERY; LIVER CIRCULATION; MALE; PORTAL VEIN; RENAL ARTERY; RENAL CIRCULATION; SWINE; TIME FACTORS;

EID: 84908501466     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00150.2014     Document Type: Article

References (43)

1. Aoki T, Imamura H, Kaneko J, Sakamoto Y, Matsuyama Y, Kokudo N, Sugawara Y, Makuuchi M. Intraoperative direct measurement of hepatic arterial buffer response in patients with or without cirrhosis. Liver Transpl 11: 684–691, 2005.
2. Arroyo V, Bosch J, Mauri M, Viver J, Mas A, Rivera F, Rodes J. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 9: 69–73, 1979.
3. Arroyo V, Gines P. Mechanism of sodium retention and ascites formation in cirrhosis. J Hepatol 17, Suppl 2: S24–S28, 1993.
4. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149–1156, 2000.
5. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodes J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125: 117–125, 2003.
6. Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodila-tion and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 20: 2555–2563, 2014.
7. Caponnetto S, Becchi G, Iannetti M, Martini U, Pastorini C, Rosselli P. [Study of the splanchnic circulation and its changes induced by the action of adrenaline, noradrenaline and hypertensin]. Rev Int Hepatol 18: 445–449, 1968.
8. Catt KJ, Mendelsohn FA, Millan MA, Aguilera G. The role of angio-tensin II receptors in vascular regulation. J Cardiovasc Pharmacol 6, Suppl 4: S575–S586, 1984.
9. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Haemo-dynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 10: 256–260, 1995.
10. Correa TD, Vuda M, Blaser AR, Takala J, Djafarzadeh S, Dunser MW, Silva E, Lensch M, Wilkens L, Jakob SM. Effect of treatment delay on disease severity and need for resuscitation in porcine fecal peritonitis. Crit Care Med 40: 2841–2849, 2012.
11. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87: E1–E9, 2000.
12. Ezzat WR, Lautt WW. Hepatic arterial pressure-flow autoregulation is adenosine mediated. Am J Physiol Heart Circ Physiol 252: H836–H845, 1987.
13. Gasic S, Heinz G, Kleinbloesem C, Korn A. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man. Br J Clin Pharmacol 27, Suppl 2: 225S–234S, 1989.
14. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Casini Raggi V, Foschi M, Marra F, Pinzani M, Buzzelli G, Laffi G,. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104: 588–594, 1993.
15. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci 123: 225–239, 2012.
16. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Bosch J, Garcia-Pagan JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 47: 220–227, 2007.
17. Graham MR, Thiessen DB, Mutch WA. Left ventricular systolic and diastolic function is unaltered during propofol infusion in newborn swine. Anesth Analg 86: 717–723, 1998.
18. Gulberg V, Haag K, Rossle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 35: 630–634, 2002.
19. Herath CB, Grace JA, Angus PW. Therapeutic potential of targeting the renin angiotensin system in portal hypertension. World J Gastrointest Pathophysiol 4: 1–11, 2013.
20. Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, Tikellis C, Burrell LM, Angus PW. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol 297: G98–G106, 2009.
21. Herath CB, Mak K, Burrell LM, Angus PW. Angiotensin-(1–7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. Am J Physiol Gastrointest Liver Physiol 304: G99–G108, 2013.
22. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 95: 540–548, 1979.
23. Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM 101: 71–85, 2008.
24. Lautt WW, Legare DJ, d’Almeida MS. Adenosine as putative regulator of hepatic arterial flow (the buffer response). Am J Physiol Heart Circ Physiol 248: H331–H338, 1985.
25. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 116: 61–69, 2003.
26. Magness RR, Cox K, Rosenfeld CR, Gant NF. Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. Am J Obstet Gynecol 171: 668–679, 1994.
27. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182–1191, 1998.
28. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H, Ishii M. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol Regul Integr Comp Physiol 261: R690–R696, 1991.
29. Motwani JG, Struthers AD. Dose-response study of the redistribution of intravascular volume by angiotensin II in man. Clin Sci 82: 397–405, 1992.
30. Nascimento EA, Gioli-Pereira L, Carvalho LT, Santos EL, Pesquero JB, Kouyoumdjian M, Borges DR. Hemodynamic and metabolic effects of angiotensin II on the liver. Peptides 26: 315–322, 2005.
31. Nicholls MG, Tree M, Brown JJ, Douglas BH, Fraser R, Hay GD, Lever AF, Morton JJ, Robertson JI. Angiotensin II/aldosterone dose-response curves in the dog: effect of changes in sodium balance. Endocrinology 102: 485–493, 1978.
32. Ohya Y, Sperelakis N. Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells. Circ Res 68: 763–771, 1991.
33. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123: 1667–1676, 2002.
34. Parviainen I, Rantala A, Ruokonen E, Tenhunen J, Takala J. Angio-tensin converting enzyme inhibition has no effect on blood pressure and splanchnic perfusion after cardiac surgery. J Crit Care 13: 73–80, 1998.
35. Pelet C, Mironneau C, Rakotoarisoa L, Neuilly G. Angiotensin II receptor subtypes and contractile responses in portal vein smooth muscle. Eur J Pharmacol 279: 15–24, 1995.
36. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB, Simoes e Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1–7). J Hepatol 46: 674–681, 2007.
37. Reisenleiter F, Katz N, Gardemann A. Control of hepatic carbohydrate metabolism and haemodynamics in perfused rat liver by arterial and portal angiotensin II. Eur J Gastroenterol Hepatol 8: 279–286, 1996.
38. Richardson PD, Withrington PG. The effects of intraportal injections of noradrenaline, adrenaline, vasopressin and angiotensin on the hepatic portal vascular bed of the dog: marked tachyphylaxis to angiotensin. Br J Pharmacol 59: 293–301, 1977.
39. Schoffmann G, Winter P, Palme R, Pollak A, Trittenwein G, Golej J. Haemodynamic changes and stress responses of piglets to surgery during total intravenous anaesthesia with propofol and fentanyl. Lab Anim 43: 243–248, 2009.
40. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157, 1988.
41. Trachte GJ, Lefer AM. Prostaglandin-mediated, angiotensin-induced vasoconstriction in isolated cat arteries. Blood Vessels 17: 196–201, 1980.
42. van den Broek SA, de Graeff PA, Smit AJ, Girbes AR Journee, van Gilst WH, Hillege H, van Veldhuisen DJ, Wesseling H, Lie KI. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol 25: 105–112, 1995.
43. Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13: R190, 2009.